Cryogenic logistics company Cryoport, Inc. has obtained another contract to support life sciences and cancer treatment technologies with its cryogenics management platform.
The California-based company has announced it will support biopharmaceutical outfit Gradalis, Inc.’s clinical trials to evaluate its investigational cellular immunotherapy for use in cancer treatments with its cryogenic solutions.
Cryoport’s global distribution network will provide the required cryogenic logistics support for multiple participating clinical sites located throughout the US. It will also extend access to patients currently enrolled in the trials.
Cryoport’s CryoportalTM logistics management platform, proprietary Cryoport Express® Shippers and advanced Smart Pak IITM Condition Monitoring Systems ship biologics, regenerative medicines and tissues, to and from other cancer centres and research facilities worldwide.
Jerrell Shelton, CEO of the US-based business, signified, “We are honoured to support Gradalis in its efforts to develop cutting-edge immunotherapy treatments. We look forward to providing Gradalis with our advanced and validated cryogenic logistics solutions, including 24/7/365 support to help move it closer to managing these life-threatening diseases.”
Last month, Cryoport entered into a contract with Moffitt Cancer Center to exclusively support its immunology programme, cancer research and therapy programmes with its cryogenic logistics.